

1. DATE ISSUED MM/DD/YYYY 10/25/2019		1a. SUPERSEDES AWARD NOTICE dated except that any additions or restrictions previously imposed remain in effect unless specifically rescinded	
2. CFDA No. 93.270 - Adult Viral Hepatitis Prevention and Control			
3. ASSISTANCE TYPE Cooperative Agreement			
4. GRANT NO. 5 NU51PS005112-04-00 Formerly		5. TYPE OF AWARD Other	
4a. FAIN NU51PS005112		5a. ACTION TYPE Non-Competing Continuation	
6. PROJECT PERIOD MM/DD/YYYY From 11/01/2016		Through 10/31/2020	
7. BUDGET PERIOD MM/DD/YYYY From 11/01/2019		Through 10/31/2020	

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC Office of Financial Resources

2939 Brandywine Road  
Atlanta, GA 30341

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations)

Sections 301 and 317N of the Public Health Service Act (42 U.S.C. section 241 and 247b-15, as amended)

8. TITLE OF PROJECT (OR PROGRAM)  
Improving Hepatitis B and C Care Cascades; Focus on Increased Testing and Diagnosis

9a. GRANTEE NAME AND ADDRESS HEALTH AND SENIOR SERVICES, MISSOURI DEPARTMENT OF PO BOX 570 MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES Jefferson City, MO 65102-0570	9b. GRANTEE PROJECT DIRECTOR Ms. Nicole. Massey 920 Wildwood Jefferson City, MO 65102-0570 Phone: 573-751-6431
--	--

10a. GRANTEE AUTHORIZING OFFICIAL Ms. Tonya R Loucks 920 Wildwood Drive Jefferson City, MO 65109-5796 Phone: 573-751-6014	10b. FEDERAL PROJECT OFFICER Mr. Wentzel Mitchell 12 Corporate Square Blvd, NE Atlanta, GA 30329 Phone: 404-718-3226
---	--

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)		12. AWARD COMPUTATION	
I Financial Assistance from the Federal Awarding Agency Only		a. Amount of Federal Financial Assistance (from item 11m) 73,063.00	
II Total project costs including grant funds and all other financial participation		b. Less Unobligated Balance From Prior Budget Periods 0.00	
a. Salaries and Wages	34,962.00	c. Less Cumulative Prior Award(s) This Budget Period 0.00	
b. Fringe Benefits	20,900.00	d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION 73,063.00	
c. Total Personnel Costs	55,862.00	13. Total Federal Funds Awarded to Date for Project Period 547,341.00	
d. Equipment	0.00	14. RECOMMENDED FUTURE SUPPORT	
e. Supplies	405.00	(Subject to the availability of funds and satisfactory progress of the project):	
f. Travel	3,123.00	YEAR	TOTAL DIRECT COSTS
g. Construction	0.00	a. 5	d. 8
h. Other	1,773.00	b. 6	e. 9
i. Contractual	0.00	c. 7	f. 10
j. TOTAL DIRECT COSTS	61,163.00	15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:	
k. INDIRECT COSTS	11,900.00	a. DEDUCTION	
l. TOTAL APPROVED BUDGET	73,063.00	b. ADDITIONAL COSTS	
m. Federal Share	73,063.00	c. MATCHING	
n. Non-Federal Share	0.00	d. OTHER RESEARCH (Add / Deduct Option)	
		e. OTHER (See REMARKS)	
		16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:	
		a. The grant program legislation.	
		b. The grant program regulations.	
		c. This award notice including terms and conditions, if any, noted below under REMARKS.	
		d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.	
		In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.	

REMARKS (Other Terms and Conditions Attached - NCC Award Partial Funding)  Yes  No

GRANTS MANAGEMENT OFFICIAL:

Constance J Jarvis, Grants Management Officer  
2960 Brandywine Rd  
Mailstop E15  
Atlanta, GA 30341-5509  
Phone: 770-488-5859

17. OBJ CLASS 41.51	18a. VENDOR CODE	18b. EIN	19. DUNS 878092600	20. CONG. DIST. 04
FY-ACCOUNT NO.	DOCUMENT NO.	CFDA	ADMINISTRATIVE CODE	AMT ACTION FIN ASST
21. a. 0-939ZRPN	b. 005112PS17	c. 93.270	d. PS	e. \$73,063.00
22. a.	b.	c.	d.	e.
23. a.	b.	c.	d.	e.

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED 10/25/2019
GRANT NO. 5 NU51PS005112-04-00	

**Direct Assistance**

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
<b>Total</b>	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED 10/25/2019
GRANT NO. 5 NU51PS005112-04-00	

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
11/01/2016	10/31/2017	Annual	01/29/2018
11/01/2017	10/31/2018	Annual	01/29/2019
11/01/2018	10/31/2019	Annual	01/29/2020
11/01/2019	10/31/2020	Annual	01/29/2021

# AWARD ATTACHMENTS

Missouri Department of Health

5 NU51PS005112-04-00

---

1. T&C for this award

**Notice of Funding Opportunity (NOFO): PS17-1702**

**Award Number: NU51PS005112-04**

**Award Type: Cooperative Agreement**

**AWARD INFORMATION**

**Incorporation:** In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number PS17-1702, entitled “**Improving Hepatitis B and C Care Cascades; Focus on Increased Testing and Diagnosis, and application** dated **August 9, 2019**, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

**Approved Funding:** Funding in the amount of **\$125,250** is approved for the **Year 2020** budget period, which is **November 1, 2019** through **October 31, 2020**. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

**Available Funding:** The CDC is operating under a Continuing Resolution; as a result, the total available funding for the Fiscal Year (FY) **2020** budget period is contingent upon the enactment of applicable appropriation bill(s). Funding in the amount of **\$73,063** in Financial Assistance (FA) is awarded on this NoA. The remainder of the budget period Approved Funding amount is subject to the availability of funds.

**Use of Unobligated Funds:** This NoA includes use of **Year 03** unobligated funds in the amount of **\$0**, *which has been applied as an offset to the currently approved funding level* for this budget period. The use of unobligated funds is approved based on the Year 03 Federal Financial Report (FFR) dated August 9, 2019. The amount of this NoA will be subject to reduction if the final amount of unobligated funds is less than the amount of unobligated funds reported on the referenced FFR.

The awarding of the remaining **\$52,188** during the budget period is subject to funds availability.

**After the budget period has expired, CDC may de-obligate all funds not expended and disbursed, including unliquidated obligations.**

Note: Refer to the Payment Information section for draw down and Payment Management System (PMS) subaccount information.

**Financial Assistance Mechanism:** Cooperative Agreement

**Substantial Involvement by CDC:** This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

**Technical Review Response Requirement:** The review comments on the strengths and weaknesses of the proposal are provided as a part of this award and are located in

**GrantSolutions.** A response to the weaknesses in these statements must be uploaded for approval into Grant Solutions as a Note and submitted to the Project Officer noted in the CDC Staff Contacts section of this NoA no later than **30 days from the budget period start date**. Provide the award number in the subject line.

Failure to submit the required information by the due date, **December 01, 2019**, will cause delay in programmatic progress and will adversely affect the future funding of this project.

**Budget Revision Requirement:** By **December 1, 2019** the recipient must submit a revised budget with a narrative justification. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

**Expanded Authority:** The recipient is permitted the following expanded authority in the administration of the award.

Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

**Program Income:** Any program income generated under this grant or cooperative agreement will be used in accordance with the Cost sharing or matching alternative.

**Cost sharing or matching alternative:** Under this alternative, program income is used to finance some or the entire non-federal share of the project/program.

**Note: The disposition of program income must have written prior approval from the GMO.**

#### **FUNDING RESTRICTIONS AND LIMITATIONS**

**Notice of Funding Opportunity (NOFO) Restrictions:** N/A

**Administrative Restriction(s):** The funds awarded for Indirect Costs in the amount of **\$11,900** are **restricted** until a current Indirect Cost Rate Agreement or Cost Allocation Plan is submitted to the GMS covering the awarded period. Document is to be submitted on or before **November 30, 2019**. If rate agreement is not submitted by the due date, an explanation is required and the funds remain restricted from use unless rescinded by the GMS in writing.

**Programmatic Restriction(s):** N/A

**Indirect Costs:** Expired

#### **REPORTING REQUIREMENTS**

**Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS):** Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely

manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services  
Valerie McCloud, Grants Management Officer/Specialist  
Centers for Disease Control and Prevention  
Infectious Diseases Services Branch (IDSB)  
Offices of Grants Services (OGS)  
Office of Financial Resources (OFR)Centers for Disease Control and Prevention  
Telephone: 770-488-4790 (Include "Mandatory Grant Disclosures" in subject line)  
Email:VMCCLOUD@CDC.GOV (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services  
Office of the Inspector General  
ATTN: Mandatory Grant Disclosures, Intake Coordinator  
330 Independence Avenue, SW  
Cohen Building, Room 5527  
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or  
Email: [MandatoryGranteeDisclosures@oig.hhs.gov](mailto:MandatoryGranteeDisclosures@oig.hhs.gov)

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

#### **PROGRAM OR FUNDING GENERAL REQUIREMENTS**

**HIV Program Review Panel Requirement:** All written materials, audiovisual materials, pictorials, questionnaires, survey instruments, websites, educational curricula and other relevant program materials must be reviewed and approved by an established program review panel. A list of reviewed materials and approval dates must be submitted to the CDC Grants Management Specialist identified in the CDC Roles and Responsibilities section of this NoA.

#### **PAYMENT INFORMATION**

*The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-*

800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to [hhstips@oig.hhs.gov](mailto:hhstips@oig.hhs.gov) or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

**Automatic Drawdown (Direct/Advance Payments):** Payments under CDC awards will be made available through the Department of Health and Human Services (HHS) Payment Management System (PMS), under automatic drawdown, unless specified otherwise in the NOA. Recipients must comply with requirements imposed by the PMS on-line system. Questions concerning award payments or audit inquiries should be directed to the payment management services office.

PMS Website: <https://pms.psc.gov/>  
PMS Phone Support: +1(877)614-5533  
PMS Email Support: [PMSSupport@psc.gov](mailto:PMSSupport@psc.gov)

**Payment Management System Subaccount:** Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, *herein identified as the "P Account"*. Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number (below) must be known in order to draw down funds from this P Account.

**Document Number:** **005112PS17**

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

**Certification Statement:** By drawing down funds, the recipient certifies that proper financial management controls and accounting systems, to include personnel policies and procedures, have been established to adequately administer federal awards and funds drawn down. Recipients must comply with all terms and conditions in the NOFO, outlined in their NOA, grant policy terms and conditions contained in applicable HHS Grant Policy Statements, and requirements imposed by program statutes and regulations and HHS grants administration regulations, as applicable; as well as any regulations or limitations in any applicable appropriations acts.

#### **PROGRAM OR FUNDING SPECIFIC CLOSEOUT REQUIREMENTS**

**Recipients must submit closeout reports in a timely manner.** Unless the Grants Management Specialist/Grants Management Officer (GMS/GMO) approves a deadline extension the recipient must submit all closeout reports within 90 days (*January 29, 2021*) of the period of performance end date. Reporting timeframe is **November 01, 2016** through **October 31, 2020**. Failure to submit timely and accurate final reports may affect future funding to the organization or awards under the direction of the same Project Director/Principal Investigator (PD/PI).

All manuscripts published as a result of the work supported in part or whole by the cooperative grant must be submitted with the performance progress reports.



The final and other programmatic reports required by the terms and conditions of the NoA are the following.

**Final Performance Progress and Evaluation Report (PPER):** This report should include the information specified in the NOFO and is submitted after solicitation from the GMS/GMO via [www.grantsolutions.gov](http://www.grantsolutions.gov) . At a minimum, the report will include the following:

- Statement of progress made toward the achievement of originally stated aims.
- Description of results (positive or negative) considered significant.
- List of publications resulting from the project, with plans, if any, for further publication.

Information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132, “Performance Progress and Monitoring Report”, Expiration Date 8/31/2019.**

**Final Federal Financial Report (FFR, SF-425):** The FFR should only include those funds authorized and actually expended during the timeframe covered by the report. The Final FFR, SF-425 is required and must be submitted to the GMO/GMS no later than 90 days (January 29, 2021) after the period of performance end date. To submit the FFR, login to [www.grantsolutions.gov](http://www.grantsolutions.gov), select “Reports” from the menu bar and then click on Federal Financial Reports.

This report must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. Should the amount not match with the final expenditures reported to the Department of Health and Human Services’ Payment Management Services (PMS), you will be required to update your reports to PMS accordingly. Remaining unobligated funds will be de-obligated and returned to the U.S. Treasury. If the final reports (FFR and PPER) cannot be submitted within 90 days after the end of the period of performance, in accordance with 45 CFR Part 75.381 (Closeout), the recipient must submit a letter requesting an extension that includes the justification for the delay and state the expected date the CDC Office of Grants Services will receive the reports. All required documents must be submitted to the business contact identified in CDC Staff Contacts.

**Equipment Inventory Report:** A complete inventory must be submitted with final PPER documents for all major equipment acquired or furnished under this project with a unit acquisition cost of \$5,000 or more. The inventory list must include the description of the item, manufacturer serial and/or identification number, acquisition date and cost, percentage of Federal funds used in the acquisition of the item. The recipient should also identify each item of equipment that it wishes to retain for continued use in accordance with 45 CFR Part 75. These requirements do apply to equipment purchased with non-federal funds for this program. The awarding agency may exercise its rights to require the transfer of equipment purchased under the assistance award referenced in the cover letter. CDC will notify the recipient if transfer to title will be required and provide disposition instruction on all major equipment. Equipment with a unit acquisition cost of less than \$5,000 that is no longer to be used in projects or programs currently or previously sponsored by the Federal Government may be retained, sold, or otherwise disposed of, with no further obligation to the Federal Government. If no equipment was acquired under this award, a negative report is required.

**Final Invention Statement:** A Final Invention Statement must be submitted with the final PPER documents. Electronic versions of the form can be downloaded by visiting <http://grants1.nih.gov/grants/hhs568.pdf>. If no inventions were conceived under this assistance award, a negative report is required. This statement may be included in a cover letter.

#### **CDC Staff Contacts**

**Grants Management Specialist:** The GMS is the federal staff member responsible for the day-

to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

**Grants Management Specialist Contact:**

Valerie McCloud, Grants Management Specialist  
Centers for Disease Control and Prevention  
Infectious Diseases Services Branch

Office of Grants Services (OGS)  
Office of Financial Resources (OFR)  
Telephone: 770-488-4790  
Email: VMCCLOUD@cdc.GOV

**Program/Project Officer:** The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements. **(See Cover page for Project Officer Information)**

**Grants Management Officer:** The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization. **(See Cover page for Grants Management Officer Information)**